ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1258

Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus

Romy Kallas1, Jessica Li2, Daniel Goldman3 and Michelle Petri3, 1Johns Hopkins Medical Institution, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Johns Hopkins University School of Medicine, Timonium, MD

Meeting: ACR Convergence 2020

Keywords: Damage Index, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: African-Americans have a higher incidence/prevalence of SLE, more lupus nephritis, higher rates of end stage renal disease and higher mortality than Caucasians. The aim of this study was to look at the trajectory of cumulative and individual organ damage accrual in a large longitudinal prospective SLE cohort in which African-American and Caucasian ethnicities were well represented, with a mean follow-up time of 13 years.

Methods: We analyzed data on 2,436 patients (43% African-American, 57% Caucasian, and 92% female) until January 2020. Patients met the revised ACR or SLICC classification criteria. The SLICC/ACR Damage Index (DI) was calculated based on organ damage that occurred after diagnosis until the last visit. Poisson regression allowing for overdispersion for each organ system with an offset term accounting for time followed since diagnosis was used. The outcome variable was the damage score of each organ system at the last available cohort visit. The associations were adjusted for sex, age, income, education, and insurance. We used Cox regression model to determine the association between individual damage items and ethnicity. These associations were adjusted for sex, age, and education.

Results: The mean total SLICC/ACR DI was 1.9 (SD=2.3). There was a linear relationship between time since diagnosis and mean DI with no plateau. By 5 years after SLE diagnosis, 44% of African-Americans vs. 36% of Caucasians had accrued damage. The rate of cumulative damage accrual was significantly higher in African-Americans (p-value 0.01). The mean time to onset of damage was 6.6 (SD 7.1) years from SLE diagnosis in Caucasian and 5.5 (SD 6.3) years in African-Americans. The divergence of the curves started early in the disease course. Renal (p-value < 0.0001), pulmonary (p-value 0.0066), and skin (p-value < 0.0001) damage in African-Americans accumulated at a higher rate compared to Caucasians (Figure 1). African-Americans had a higher risk of renal insufficiency, proteinuria 3.5g/24hrs, end-stage renal disease, pulmonary hypertension, pulmonary fibrosis, cardiomyopathy, pericardial damage, deforming or erosive arthritis, avascular necrosis, skin damage, and diabetes than Caucasians at any time during follow-up. On the other hand, Caucasian patients were at higher risk for osteoporosis with fracture or vertebral collapse and infarction or resection of bowel (Table 1).

Conclusion: At any point during the disease, the SLICC/ACR DI was higher and accrued at a faster rate in African-American compared to Caucasian SLE. Damage in most organ systems progressed at a faster rate in African-Americans with the exception of osteopenic fracture and bowel infarction/resection. Of particular concern was the linear increase in damage in both ethnicities over time.

Figure 1: Damage accrual rate of each organ over time in African-American and Caucasian patients


Disclosure: R. Kallas, None; J. Li, None; D. Goldman, None; M. Petri, Astrazeneca, 2, 5, Exagen, 2, 5, GlaxoSmithKline (GSK), 2, 5, Eli Lilly and Company, 2, 5, AbbVie Inc., 5, Aleon Pharma International, Inc, 5, Amgen, 5, Annenberg Center for Health Sciences,, 5, Blackrock Pharma, 5, Bristol Myers Squibb, 5, Decision Resources, 5, Glenmark Pharmaceuticals, 5, INOVA, 5, IQVIA, 5, Janssen Pharmaceutical, 5, Merck EMD Serono, 5, Novartis, 5, Sanofi Japan, 5, Thermofisher, 5, UCB, 5.

To cite this abstract in AMA style:

Kallas R, Li J, Goldman D, Petri M. Trajectory of Damage Accrual in African-American vs. Caucasian Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/trajectory-of-damage-accrual-in-african-american-vs-caucasian-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trajectory-of-damage-accrual-in-african-american-vs-caucasian-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology